Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China and internationally. The company offers pathological diagnostic reagents and ancillary equipment that consists of liquid-based cytology products, including liquid-based cytology production machines and automatic sample transfer machines; polymerase ...
Guangzhou LBP Medicine Science & Technology reported revenue of 344.45 million CNY for fiscal year 2025, down 26.8% from fiscal year 2024, and net income of -47.02 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 79.55 million CNY, up 9.7% from a year before. East China was its largest region in fiscal year 2021, with 31% of revenue.
Figures from company filings; latest fiscal year ended December 31, 2025.
No profile data available.